Bashir Ahmad

Bashir Ahmad

Auto-generated profile, based on publicly available information

Bashir Ahmad

Affiliations Department of Pediatrics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China, Department of Biology, The University of Haripur, Khyber Pakhtunkhwa, Pakistan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
BABashir Ahmad
Bashir Ahmad
SKSuliman Khan
Suliman Khan
YLYang Liu
Yang Liu
MXMengzhou Xue
Mengzhou Xue
GNGhulam Nabi
Ghulam Nabi
AQAbdul Wakeel Qarluq
Abdul Wakeel Qarluq
Medicinal plants are a vital source of natural products (NPs) that can cure cancer through modulation of different pathways, including oxidative stress, extrinsic and intrinsic apoptosis, cell cycle, inflammation, NF-kB, PI3K/AKT/mTOR, AMPK (JNK), MEK/ERK (Raf)-MEK-ERK and autophagy. Puerarin (Pue), an important NP belonging to the isoflavone glycoside group, is derived from Pueraria lobata (Willd.) Ohwi, Pueraria thomsonii Benth, and Pueraria tuberosa (Willd.). This NP was approved by the Chinese Ministry of Health for the treatment of different diseases in 1993, but it was also later reported to exhibit anticancer activity. Pue causes cancer cells death through modulation of different mechanisms including oxidative stress, intrinsic and extrinsic, Survivin and XIAP, PI3K/AKT/mTOR, Ras-Raf-MEK-ERK, JNK, cell cycle, AMPK, NF-kB, inflammation and autophagy pathways. Therefore, this review compiles for the first time the studies about the anticancer mechanism of Pue and provides comprehensive information about the anticancer effects of Pue. This review may serve as a basis for future research and clinical treatment.

1 June 2020 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
PSPengyu Su
Pengyu Su
BABashir Ahmad
Bashir Ahmad
KZKun Zou
Kun Zou
ZLZou Lijuan
Zou Lijuan
Background: The most common chemotherapeutic drug for triple-negative breast cancer (TNBC) treatment is 5-fluorouracil (5-FU), but its therapeutic index is low due to its toxicity. β-Elemene (ELE) possesses antitumor activity against different cancers, but it has never been used in combination with 5-FU to improve its chemotherapeutic effect against TNBC. Materials and Methods: We treated MDA-MB-231 and BT549 cells of TNBC with ELE alone, 5-FU alone, or their combination to investigate their treatment effects on cell viability, proliferation, migration, invasion, and colony formation. We verified the molecular mechanisms of our results through confocal immunofluorescence, immunohistochemistry, and Western blot analysis in vitro and in vivo. Results: Our result revealed that ELE enhanced the 5-FU effect against cell viability, proliferation, migration, invasion, and colony formation through different mechanisms in MDA-MB-231 and BT549 cell lines. In molecular mechanisms, ELE and 5-FU in combination enhances apoptosis in both cell lines through Bl-2 family protein and caspase cascade modulation, thereby inhibiting NF-kB pathway through IKKβ, IKKα, and p65 downregulation in the cytoplasm and p50 and p65 downregulation in the nucleus. ELE and 5-FU in combination regulated the PI3K/AKT pathway through p-AKT, P-85, p110r, p-PDK1, and p110a protein and RAF-MEK-ERK pathway inhibition through the p-c-raf and p-ERK downregulation. The PI3K inhibitor LY294002 or RAF-MEK-ERK inhibitor U0126 in combination with ELE and 5-FU decreased cell viability in both cell lines significantly, thereby showing the involvement of these pathways in cell apoptosis. In mouse xenograft model, ELE and 5-FU in combination inhibited the tumor growth and modulated its molecular markers. Conclusion: The conclusion obtained, considering that the results suggest that the combination may be important specifically in the treatment of TNBC.

20 December 2020 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
BABashir Ahmad
Bashir Ahmad
SRShafiq Ur Rehman
Shafiq Ur Rehman
AAAzizullah Azizullah
Azizullah Azizullah
MKMuhammad Fiaz Khan
Muhammad Fiaz Khan
SDSyed Riaz Ud Din
Syed Riaz Ud Din
Deog-Hwan OhDeog-Hwan Oh
Deog-Hwan Oh

1 March 2021 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
BABashir Ahmad
Bashir Ahmad
YGYaser Gamallat
Yaser Gamallat
MKMuhammad Fiaz Khan
Muhammad Fiaz Khan
SDSyed Riaz Din
Syed Riaz Din
MIMuhammad Israr
Muhammad Israr
LWLiang Wang
Liang Wang
Cancer is the second leading cause of mortality worldwide. Conventional therapies, including surgery, radiation, and chemotherapy, have limited success because of secondary resistance. Therefore, safe, non-resistant, less toxic, and convenient drugs are urgently required. Natural products (NPs), primarily sourced from medicinal plants, are ideal for cancer treatment because of their low toxicity and high success. NPs cure cancer by regulating different pathways, such as PI3K/AKT/mTOR, ER stress, JNK, Wnt, STAT3, MAPKs, NF-kB, MEK-ERK, inflammation, oxidative stress, apoptosis, autophagy, mitophagy, and necroptosis. Among the NPs, steroid saponins, including polyphyllins (I, II, D, VI, and VII), have potent pharmacological, analgesic, and anticancer activities for the induction of cytotoxicity. Recent research has demonstrated that polyphyllins (PPs) possess potent effects against different cancers through apoptosis, autophagy, inflammation, and necroptosis. This review summarizes the available studies on PPs against cancer to provide a basis for future research.

11 August 2020 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
BABashir Ahmad
Bashir Ahmad
YGYaser Gamallat
Yaser Gamallat
PSPengyu Su
Pengyu Su
AHAkbar Husain
Akbar Husain
ARAta Ur Rehman
Ata Ur Rehman
LWLiang Wang
Liang Wang

5 February 2020 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
SJSajid Jalal
Sajid Jalal
BABashir Ahmad
Bashir Ahmad
TZTing Zhang
Ting Zhang
LGLianying Guo
Lianying Guo
LHLin Huang
Lin Huang